HPV Testing and Pap Test Market Hits USD 5.6 Billion By 2024: Grand View Research, Inc.
The global Human Papillomavirus (HPV) testing and Pap test market are
expected to reach USD 5.6 billion by 2024, according to a new report by Grand
View Research Inc.The market is majorly driven by the increasing number of
cervical cancer cases, government initiatives, and the heightened awareness
amongst women about cervical cancer. For instance, the CDC advocates cervical
cancer screening tests for women above the age of 30 as it was found that the
cervical cancers are rare in the age group, 20-30 years (2 in 100,000) as
compared to the older age groups (16 in 100,000).
In addition to carrying out awareness campaigns, the
government and key industrial players are providing funding to universities for
the development of enhanced technologies to facilitate effective screening,
which would mitigate the incidence of late-stage cervical cancer. In this
direction,in April 2014, the FDA approved the use of the HPV DNA test, also
referred to as the Cobas HPV test (Roche Molecular Systems), as a primary
screening test.
A study conducted by the scientists of Hologic, Inc. and University
of Pittsburgh Medical Center hasshownthe importance of combined testing (HPV
and Pap) stating that the Paptest identifies cellular abnormalities and the HPV
test detects suspicious viruses, hence improving the efficiency and providing
the best results that are cost-effective and convenient to the patients.
Browse full research report on HPV Testing and Pap Test
Market: http://www.grandviewresearch.com/industry-analysis/hpv-testing-pap-test-market
Further key findings from the report suggest:
- The
cervical cancer screening segment dominated the market in 2015 owing to
the introduction of advanced technologies for the screening and detection
of cervical cancer. For instance, in May 2016,Hologic Inc. determined that
HPV and Pap co-testing was the most effective in the screening of cervical
cancer.
- The
laboratories segment dominated the HAV and Pap test market in 2015 owing
to the increased performance in the diagnosis of cervical cancer cases. As
per the CDC statistics, approximately 21.7 million tests were performed in
the U.S.; hence,the hospitalssegmentis expected to witnessa rapid growthin
the coming years due to the increasing number of diagnostic tests
performed in-house and also the availability of advanced technologies.
- In
2015, North America held the largest share in terms of revenue owing to
the continual introduction ofinnovated technologies to improve patient
care and diagnosis. In addition, the high number of positive cases being
detected,along with the rising death toll (i.e., 2.6 in 1,00,000), has
compelled the government to conduct awareness programmes about the early
diagnosis and treatment of cervical cancer, which is a key factor for the
large market share.
- In
April 2014, the FDA approved the use of the HPV DNA test, also referred to
as the Cobas HPV test. Roche introduced a test that detectsthe DNAsequence
of cancer-causing high-risk HPVs. It provides information
regardingpatients’ risk of developing cervical cancer. The Cobas HPV test
is used to specifically identify HPV 16 and HPV 18as well as12 other
high-risk HPVs from the cervical cell sample in women older than 25 years
of age.
- AsiaPacific
is expected to grow at a high CAGR in the coming years. As per the cancer
council, 61% of the Australian women are screened for cervical cancer
every two years, out of which around 26% who have been detected throughthe
normal Pap test undergo an early re-screening more often than the
recommended two years of interval.
- Some
key players in the market are QiagenN. V., Hologic, Inc., Roche Holding
AG, Abbott Laboratories, and Becton, Dickinson and Company.These market
players are in the process of introducing tests to change the traditional
methods of individual HPV and Pap tests and introducenewer techniques or
devices to improve the efficiency and convenience.
- For
instance, in February 2016, Quest acquiredClinical Laboratory Partner’s
outreach laboratory service business. This acquisition is expected to
provide the patients a broader service network with better quality,
affordability, and convenience.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the global HPV testing and
Pap test market on the basis of type, application, end-use, and regions:
HPV Testing and Pap Test Outlook by Type (Revenue, USD
Million, 2013 – 2024)
- Pap
Test
- HPV
Test
HPV Testing and Pap Test Application Outlook (Revenue,
USD Million, 2013 – 2024)
- Cervical
Cancer
- Vaginal
Cancer
HPV Testing and Pap Test End-use Outlook (Revenue, USD
Million, 2013 – 2024)
- Point-of-Care
- Central
Laboratories
- Others
HPV Testing and Pap Test Regional Outlook (Revenue, USD
Million, 2013 – 2024)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Rest
of Europe
- Asia
Pacific
- India
- Japan
- China
- Rest
of Asia Pacific
- Latin
America
- Brazil
- Rest
of Latin America
- MEA
- South
Africa
Access press release of this research report by Grand
View Research: http://www.grandviewresearch.com/press-release/global-hpv-test-pap-test-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make
informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
For more information:
www.grandviewresearch.com
Comments
Post a Comment